DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC.
Fabrice André(Inserm), Komal Jhaveri(Memorial Sloan Kettering Cancer Center), Shin‐Cheh Chen(Chang Gung University), Sherene Loi(The University of Melbourne), Bogdan Żurawski, Carey K. Anders(Duke University), Peter Schmid, José Luiz Pedrini(Hospital Nossa Senhora da Conceição), Sarice R Boston(University of Maryland, Baltimore), Adam Konpa(AstraZeneca (Poland)), Daniil Stroyakovskiy(Shikoku Cancer Center), Giulia Fabbri(AstraZeneca (United States)), Dinesh Chandra Doval(Rajiv Gandhi Cancer Institute and Research Centre), Barbara Pierotti(AstraZeneca (Japan)), Erika Hamilton(Sarah Cannon)
Cited by 32
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k